Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
|Articles|May 23, 2022
Daily OTC Pearl: CalmEar
Author(s)Saro Arakelians, PharmD
CalmEar is for dry, irritated, and itchy ears.
Advertisement
OTC/Lifestyle Pearl of the Day: CalmEar
Indication: CalmEar is for dry, irritated, and itchy ears.
Insights:
- Directions: Use at bedtime.
- 3 to 10 drops in the affected area
- Lubricant for earplugs and ear molds, apply a small amount to fingers, then apply to earplug or ear mold.
- Each bottle contains 298 drops.
- Safe for all ages
- Natural plant extracts with excellent skin compatibility
Source:
Advertisement
Related to this article
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
With nearly 8 in 10 older adults misusing at least 1 OTC product, clearer counseling and labels could close the gap.
Contraceptive access gaps driven by federal rollbacks, provider shortages, and stalled state legislation could be narrowed by letting trained pharmacists prescribe birth control independently.
Cancer diagnoses among civilians exposed to 9/11 dust keep rising, with strained health programs struggling to meet growing needs.
With childhood immunization rates sliding and outbreaks accelerating, pharmacist-led counseling and vaccine administration can boost vaccination rates.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
FDA Reduces Monitoring Time for First Two Tarlatamab Doses
4
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
5